It was also noteworthy that the sensitivity of tumor cells to trabectedin antineoplastic activity varied consistently among the different cell lines evaluated, as it was at maximum against NCI-H295R and less evident against MUC-1, which was derived from an ACC patient whose tumor was resistant to the standard EDP-M scheme. This evidence concerns the gene MUC1 and adrenal cortex carcinoma.